Company registration number 08835363 (England and Wales)
HISTOCYTE LABORATORIES LTD
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
PAGES FOR FILING WITH REGISTRAR
HISTOCYTE LABORATORIES LTD
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 5
HISTOCYTE LABORATORIES LTD
BALANCE SHEET
AS AT
31 DECEMBER 2023
31 December 2023
- 1 -
2023
2022
Notes
£
£
£
£
Fixed assets
Tangible assets
3
102,725
114,439
Current assets
Stocks
75,552
76,733
Debtors
4
335,476
256,321
Cash at bank and in hand
1,482,648
1,083,561
1,893,676
1,416,615
Creditors: amounts falling due within one year
5
(172,163)
(219,322)
Net current assets
1,721,513
1,197,293
Total assets less current liabilities
1,824,238
1,311,732
Provisions for liabilities
(19,147)
(21,824)
Net assets
1,805,091
1,289,908
Capital and reserves
Called up share capital
111
111
Profit and loss reserves
1,804,980
1,289,797
Total equity
1,805,091
1,289,908

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 5 February 2024 and are signed on its behalf by:
Mr C Tristram
Miss IF Hofverberg
Director
Director
Company registration number 08835363 (England and Wales)
HISTOCYTE LABORATORIES LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
- 2 -
1
Accounting policies
Company information

Histocyte Laboratories Ltd is a private company limited by shares incorporated in England and Wales. The registered office is Q10, Neon, Suite 11, Quorum Business Park, Newcastle upon Tyne, Tyne and Wear, England, NE12 8BU.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover represents net invoiced provision of design, preparation and testing services and supplies. Income is recognised as the work progresses and the company receives the right to income through performance.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold improvements
Over the term of the lease
Lab equipment
at varying rates on cost
Fixtures and fittings
20% on reducing balance
Computer equipment
20% on reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

1.4
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

HISTOCYTE LABORATORIES LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023
1
Accounting policies
(Continued)
- 3 -
1.5
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

1.6
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.7
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

1.8
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2023
2022
Number
Number
Total
10
9
HISTOCYTE LABORATORIES LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023
- 4 -
3
Tangible fixed assets
Leasehold improvements
Lab equipment
Fixtures and fittings
Computer equipment
Total
£
£
£
£
£
Cost
At 1 January 2023
72,162
80,957
12,347
8,783
174,249
Additions
-
0
5,273
145
1,334
6,752
At 31 December 2023
72,162
86,230
12,492
10,117
181,001
Depreciation and impairment
At 1 January 2023
25,637
25,233
4,979
3,961
59,810
Depreciation charged in the year
7,300
7,714
2,436
1,016
18,466
At 31 December 2023
32,937
32,947
7,415
4,977
78,276
Carrying amount
At 31 December 2023
39,225
53,283
5,077
5,140
102,725
At 31 December 2022
46,525
55,724
7,368
4,822
114,439
4
Debtors
2023
2022
Amounts falling due within one year:
£
£
Trade debtors
293,783
233,658
Other debtors
13,573
3,184
Prepayments and accrued income
28,120
19,479
335,476
256,321
5
Creditors: amounts falling due within one year
2023
2022
£
£
Trade creditors
18,079
36,217
Corporation tax
-
0
89,483
Other taxation and social security
35,587
5,654
Other creditors
16,902
13,608
Accruals and deferred income
101,595
74,360
172,163
219,322
HISTOCYTE LABORATORIES LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023
- 5 -
6
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006:

The auditor's report was unqualified.

Senior Statutory Auditor:
Michael T Moran BA FCA
Statutory Auditor:
Robson Laidler Accountants Limited
Date of audit report:
26 February 2024
7
Operating lease commitments
Lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2023
2022
£
£
Within one year
32,472
32,742
Between two and five years
173,808
13,645
206,280
46,387
8
Parent company

The company is the subsidiary is under the control of Investor Ab (Investor Aktibolag).

2023-12-312023-01-01false26 February 2024CCH SoftwareCCH Accounts Production 2024.210No description of principal activityThis audit opinion is unqualifiedMr C TristramMr E M SkoglundMiss I F Hofverbergfalsefalse088353632023-01-012023-12-31088353632023-12-31088353632022-12-3108835363core:LeaseholdImprovements2023-12-3108835363core:PlantMachinery2023-12-3108835363core:FurnitureFittings2023-12-3108835363core:ComputerEquipment2023-12-3108835363core:LeaseholdImprovements2022-12-3108835363core:PlantMachinery2022-12-3108835363core:FurnitureFittings2022-12-3108835363core:ComputerEquipment2022-12-3108835363core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-3108835363core:CurrentFinancialInstrumentscore:WithinOneYear2022-12-3108835363core:CurrentFinancialInstruments2023-12-3108835363core:CurrentFinancialInstruments2022-12-3108835363core:ShareCapital2023-12-3108835363core:ShareCapital2022-12-3108835363core:RetainedEarningsAccumulatedLosses2023-12-3108835363core:RetainedEarningsAccumulatedLosses2022-12-3108835363bus:Director12023-01-012023-12-3108835363bus:Director32023-01-012023-12-3108835363core:LeaseholdImprovements2023-01-012023-12-3108835363core:PlantMachinery2023-01-012023-12-3108835363core:FurnitureFittings2023-01-012023-12-3108835363core:ComputerEquipment2023-01-012023-12-31088353632022-01-012022-12-3108835363core:LeaseholdImprovements2022-12-3108835363core:PlantMachinery2022-12-3108835363core:FurnitureFittings2022-12-3108835363core:ComputerEquipment2022-12-31088353632022-12-3108835363core:WithinOneYear2023-12-3108835363core:WithinOneYear2022-12-3108835363core:BetweenTwoFiveYears2023-12-3108835363core:BetweenTwoFiveYears2022-12-3108835363bus:PrivateLimitedCompanyLtd2023-01-012023-12-3108835363bus:SmallCompaniesRegimeForAccounts2023-01-012023-12-3108835363bus:FRS1022023-01-012023-12-3108835363bus:Audited2023-01-012023-12-3108835363bus:Director22023-01-012023-12-3108835363bus:FullAccounts2023-01-012023-12-31xbrli:purexbrli:sharesiso4217:GBP